8-K: INVO Fertility Secures $500K from Existing Investor

INVO Fertility, Inc. announced an existing institutional investor exercised an additional investment right, acquiring $500,000 in Series C-2 Convertible Preferred Stock.

Summary

• An institutional investor, an existing holder of Series C-2 Convertible Preferred Stock (C-2 Preferred), exercised its Additional Investment Right on October 16, 2025.
• The investor acquired 500 shares of C-2 Preferred, with an aggregate stated value of $500,000, for $500,000 in cash.
• As a result of this exercise, the conversion price on the C-2 Preferred adjusted to $0.6285 per share.
• The C-2 Preferred shares were issued without registration under the Securities Act, relying on exemptions provided by Section 4(a)(2) and/or Rule 506.
• The transaction is pursuant to a Securities Purchase Agreement dated January 3, 2024, and a Joinder Agreement dated October 11, 2024.

Sentiment

Score: 7

Explanation: The cash infusion is a positive for liquidity and demonstrates continued investor confidence. However, the adjustment of the conversion price for preferred stock introduces potential future dilution, which tempers the overall positive sentiment.

Positives

• Secured $500,000 in cash from an existing institutional investor, providing additional capital.
• The exercise of an Additional Investment Right by an existing holder demonstrates continued investor confidence and support.

Negatives

• The adjustment of the C-2 Preferred conversion price to $0.6285 per share could imply future dilution for common stockholders upon conversion.

Industry Context

This specific financing event for INVO Fertility, Inc. reflects a company-specific capital raise rather than a broad industry trend. However, continued investment in fertility technology companies can indicate investor confidence in the growth potential of the assisted reproductive technology market.

Stakeholder Impact

• Shareholders: Potential for future dilution of common stock if the C-2 Preferred shares are converted.
• Company: Enhanced liquidity and working capital due to the $500,000 cash infusion.

Key Dates

Recommendation

The capital raise from an existing investor provides a positive signal of continued support and improves liquidity. However, the details of the convertible preferred stock, particularly the adjusted conversion price, suggest potential future dilution for common shareholders. Without further operational or financial updates, this event alone does not warrant a change from a 'hold' position, as it primarily represents the execution of a pre-existing financing agreement rather than a new strategic development.

Keywords

INVO Fertility, IVF, Equity Financing, Convertible Preferred Stock, Capital Raise, SEC Filing, Unregistered Sale, Institutional Investor